Currently, in ER+, HER2- metastatic breast cancer patients, CDK 4/6 inhibitors in addition to anti-oestrogens, usually aromatase inhibitors (AIs), are recommended as the first-line salvage treatment (121–124). This evidence concerns the gene ERBB2 and breast cancer.